Employees at Achilles Therapeutics are bracing themselves for job losses after the UK biotech announced that it is dropping its R&D in tumour-infiltrating lymphocyte (TIL) therapies for cancer and launching a strategic review.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,